Stockreport

Genmab Announces Submission of Supplemental Biologics License Application to FDA for Daratumumab in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma

GENMAB A/S  (GMXAY) 
NASDAQ:AMEX Investor Relations: ir.genmab.com
PDF Company Announcement sBLA submitted to U.S. FDA for daratumumab in combination with bortezomib, thalidomide and dexamethasone as treatment for newly diagnosed patients [Read more]